VANCOUVER and SAN DIEGO, Sept. 20 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious diseases, will
present at the UBS 2007 Global Life Sciences Conference being held at the
Grand Hyatt Hotel, New York City September 24-27, 2007. Dr. Jim DeMesa,
President and Chief Executive Officer, will present on Thursday, September 27
at 2:30 PM Eastern Time (11:30 AM Pacific Time). An audio webcast and a copy
of the presentation will be available on the Company's web site at
www.migenix.com the day of the presentation.
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.
James M. DeMesa, M.D.
President & CEO
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, email@example.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com